期刊文献+

不同抗凝强度华法林预防非瓣膜性房颤血栓栓塞的临床研究 被引量:2

Clinical Study of Different Anticoagulate Intensity of Warfarin in Prevention of Nonvalvular Atrial Fibrillation
原文传递
导出
摘要 目的:探讨不同抗凝强度华法林应用于非瓣膜性心房颤动患者的可行性及安全性。方法:91例非瓣膜性心房颤动患者随机分为三组:低抗凝强度[国际标准化比率(INR)1.5~1.91;标准抗凝强度组(INR2.0~2.5)和阿司匹林组,观察三组血栓栓塞并发症和出血等不良反应的发生率以及c-反应蛋白浓度变化。结果:标准抗凝强度组血栓发生率低于低抗凝强度组、阿司匹林组,不同强度华法林抗凝组血栓栓塞率比较差异无统计学意义;标准抗凝强度组出血发生率低于其他两个组,但三组患者出血发生率比较无统计学意义(P〉O.05);治疗后低抗凝强度组、标准抗凝强度组c-反应蛋白浓度明显低于治疗前(P〈O.05),治疗后阿司匹林组c-反应蛋白水平明显高于低抗凝强度组、标准抗凝强度组(P〈0.01)。结论:华法林抗凝维持INR值在2.O~2.5时能降低非瓣膜性房颤患者血栓栓塞发生率,出血发生率低,有效性和安全性好。 Objective:To investigate the efficacy and safety of Warfarin different anticoagulation intensities and aspirin preventing thrombo embolism in nonvalvular atrial fibrillation. Methods: Ninty one patients with non-valvular atrial fi- brillation were divided into three groups randomly: low-dose warfarin group (INR 1. 5 - 1.9) ;standard dose warfarin group (INR 2.0-2.5 );aspirin control group,INR-specified rates for both ischemic and major hemorrhagic events and C-reactive protein concentration were analyzed. Results:The lowest incidence of thrombo-embolism and hemorrhage were standard-dose warfarin group. The comparison of the incidence of hemorrhage in the three groups was not significant va- riance(P〉0.05). The concentrations of C-reactive protein in low-dose warfarin group and standard close warfarin group were lower than those before the treatment (P〈0.05) . After the therapy,the C-reactive protein concentration in aspirin control group was significantly higher than the other two groups (P〈0.01). Conclusion:When INR maintains standard anticoagulation intensity between 2.0 and 2.5 can safely and effectively reduce the incidence of thrombo-embolism and bleeding in patients with nonvalvular atrial fibrillation.
出处 《华西医学》 CAS 2009年第1期55-57,共3页 West China Medical Journal
关键词 非瓣膜病 血栓栓塞 华法林 阿司匹林 C-反应蛋白 nonvalvular thrombo embolism warfarin aspirin C-reactive protein
  • 相关文献

参考文献9

  • 1Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation Ⅱ Study[J]. Lancet, 1994, 343:681-691
  • 2Muir K W,Weir CJ, Alwan W, et al. C reactive protein and outcome after ischemic stroke[J]. Stroke, 1999,30 : 981-985
  • 3Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention:the Anticoagulation and Risk Factors in Atrial Fibrillation(ATRIA)Study[J]. JAMA, 2001,285 :2370-2375.
  • 4胡大一,孙艺红,周自强,李奎宝,倪永斌,杨光,孙淑红,李蕾.中国人非瓣膜性心房颤动脑卒中危险因素的病例-对照研究[J].中华内科杂志,2003,42(3):157-161. 被引量:361
  • 5Arboix A,Giarcia-Eroles L,Massons JB,et al . Atrial fibrillation and stroke:clinical presentation of cardioembolic versus atherothrombotic. Infarction[J]. Int J Cardiol,2000,73(1) :33-42.
  • 6Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation. A muhicenter, prospective, randomized trial. Japanese Nonvalvular fibrillation Embolish secondary prevention cooperative study group[J]. Stroke,2000,31:817-821.
  • 7Hylek EM,Skates SJ,Sheehan MA,et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation[J]. N Engl J Med, 1996,335 (8) : 540-546.
  • 8Jialal I,Deveraj S. Inflammation and atheroselerosis:the value of the high-sensitivity C-reactive protein in assay as a risk marker[J]. Am J Clin Pathol,2001,116 (Supp 1):108-115.
  • 9周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1401

二级参考文献1

共引文献1640

同被引文献18

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部